通过致白血病的AML1-ETO融合蛋白对E蛋白进行沉默
Jinsong Zhang1, Markus Kalkum, Soichiro Yamamura
1Laboratory of Biochemistry and Molecular Biology, Rockefeller University, 1230 York Avenue, New York, NY 10021, USA.
概括
在急性髓性白血病 (AML) 中,AML1-ETO融合蛋白通过防止协激活剂结合来阻断E蛋白的功能. 这种相互作用破坏了正常的基因调节,导致白血病的发展.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- AML1-ETO融合蛋白是由t(8;21) 染色体转位引起的.
- 这种融合蛋白与大约15%的急性髓性白血病 (AML) 病例有关.
- 了解AML1-ETO的分子机制对于向治疗至关重要.
研究的目的:
- 研究AML1-ETO如何影响E蛋白的转录活性.
- 阐明特定蛋白质域和基因在AML1-ETO介导抑制中的作用.
- 通过了解AML中的E蛋白失调来确定新的治疗点.
主要方法:
- 同免疫沉试验用于研究蛋白质相互作用.
- 西方涂抹检测蛋白质表达水平.
- 记者基因测试测量转录活动.
主要成果:
- 通过稳定的相互作用,AML1-ETO和ETO抑制了E蛋白的转录激活.
- 这些相互作用阻止了p300/CREB结合蛋白 (CBP) 联合激活剂的招募.
- 保存的ETO TAF4同质域和E蛋白中的特定基因调解这些抑制相互作用.
- 在t(8;21) 白血病细胞中,AML1-ETO通过异常的辅因子交换引起了E蛋白功能的稳定沉默.
结论:
- E蛋白是AML1-ETO的直接标,它们的失调在白血病发生过程中具有重要意义.
- 确定了一种新的E蛋白沉默机制,与差异化抑制蛋白质不同.
- 针对AML1-ETO-E蛋白相互作用可能为AML提供新的治疗策略.
相关概念视频
Non-LTR Retrotransposons
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...


